George M Shaw

List of Publications by Citations

104 papers	18,269 citations	49 h-index	108 g-index
108 ext. papers	20,522 ext. citations	14.6 avg, IF	5.45 L-index

#	Paper	IF	Citations
104	Viral dynamics in human immunodeficiency virus type 1 infection. *Nature*, **1995**, 373, 117-22	50.4	2863
103	Antibody neutralization and escape by HIV-1. *Nature*, **2003**, 422, 307-12	50.4	1978
102	Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 7552-7	11.5	1472
101	Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. *Nature Medicine*, **1997**, 3, 205-11	50.5	1041
100	Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. *Nature Medicine*, **1998**, 4, 1302-7	50.5	900
99	Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. *Nature*, **2013**, 496, 469-76	50.4	759
98	Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. *Cell*, **1986**, 45, 637-48	56.2	687
97	Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. *Journal of Experimental Medicine*, **2009**, 206, 1273-89	16.6	600
96	Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. *Nature*, **1994**, 370, 463-7	50.4	557
95	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. *Journal of Experimental Medicine*, **2009**, 206, 1253-72	16.6	500
94	Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. *Journal of Virology*, **2008**, 82, 3952-70	6.6	487
93	Human infection by genetically diverse SIVSM-related HIV-2 in west Africa. *Nature*, **1992**, 358, 495-9	50.4	391
92	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. *Journal of Virology*, **2011**, 85, 9998-10009	6.6	342
91	Phenotypic properties of transmitted founder HIV-1. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 6626-33	11.5	293
90	Antigenic conservation and immunogenicity of the HIV coreceptor binding site. *Journal of Experimental Medicine*, **2005**, 201, 1407-19	16.6	264
89	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. *Journal of Experimental Medicine*, **2009**, 206, 1117-34	16.6	257
88	Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. *PLoS Pathogens*, **2009**, 5, e1000274	7.6	253

87	High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. *PLoS Pathogens*, **2010**, 6, e1000890	7.6	219
86	Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. *Cell*, **2014**, 158, 481-91	30.2	213
85	Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody. *Cell*, **2016**, 165, 449-63	56.2	209
84	HIV transmission. *Cold Spring Harbor Perspectives in Medicine*, **2012**, 2,	5.4	197
83	An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. *Journal of Virology*, **2011**, 85, 7029-36	6.6	180
82	Wide variation in the multiplicity of HIV-1 infection among injection drug users. *Journal of Virology*, **2010**, 84, 6241-7	6.6	167
81	HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. *PLoS Pathogens*, **2009**, 5, e1000414	7.6	146
80	Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. *PLoS Pathogens*, **2012**, 8, e1002721	7.6	143
79	Relative resistance of HIV-1 founder viruses to control by interferon-alpha. *Retrovirology*, **2013**, 10, 146	3.6	142
78	Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. *Journal of Clinical Investigation*, **2013**, 123, 380-93	15.9	141
77	African origin of the malaria parasite Plasmodium vivax. *Nature Communications*, **2014**, 5, 3346	17.4	137
76	Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E3413-22	11.5	132
75	Modeling sequence evolution in acute HIV-1 infection. *Journal of Theoretical Biology*, **2009**, 261, 341-60	2.3	128
74	Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. *Science Translational Medicine*, **2017**, 9,	17.5	127
73	Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. *PLoS Pathogens*, **2012**, 8, e1002881	7.6	118
72	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. *PLoS Pathogens*, **2015**, 11, e1005042	7.6	111
71	HIV-Host Interactions: Implications for Vaccine Design. *Cell Host and Microbe*, **2016**, 19, 292-303	23.4	108
70	Low-dose mucosal simian immunodeficiency virus infection restricts early replication kinetics and transmitted virus variants in rhesus monkeys. *Journal of Virology*, **2010**, 84, 10406-12	6.6	105

69	Genomes of cryptic chimpanzee Plasmodium species reveal key evolutionary events leading to human malaria. *Nature Communications*, **2016**, 7, 11078	17.4	100
68	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. *Immunity*, **2019**, 50, 241-252.e6	32.3	96
67	Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E590-E599	11.5	92
66	HIV-1 Vpu Mediates HLA-C Downregulation. *Cell Host and Microbe*, **2016**, 19, 686-95	23.4	81
65	Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. *Journal of Virology*, **2013**, 87, 4185-201	6.6	80
64	Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. *JCI Insight*, **2017**, 2,	9.9	75
63	Evidence of two distinct subsubtypes within the HIV-1 subtype A radiation. *AIDS Research and Human Retroviruses*, **2001**, 17, 675-88	1.6	73
62	Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. *PLoS Pathogens*, **2012**, 8, e1002880	7.6	67
61	Completeness of HIV-1 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. *Cell Reports*, **2018**, 25, 893-908.e7	10.6	65
60	Human immunodeficiency virus type 2 (HIV-2)/HIV-1 envelope chimeras detect high titers of broadly reactive HIV-1 V3-specific antibodies in human plasma. *Journal of Virology*, **2009**, 83, 1240-59	6.6	61
59	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. *Nature Medicine*, **2020**, 26, 932-940	50.5	60
58	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. *Cell Host and Microbe*, **2015**, 18, 354-62	23.4	53
57	Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. *EBioMedicine*, **2016**, 3, 122-134	8.8	53
56	Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. *Virology*, **2013**, 436, 33-48	3.6	50
55	Cytotoxic T-lymphocyte escape viral variants: how important are they in viral evasion of immune clearance in vivo?. *Immunological Reviews*, **1998**, 164, 37-51	11.3	49
54	Broadly Neutralizing Antibody Mediated Clearance of Human Hepatitis C Virus Infection. *Cell Host and Microbe*, **2018**, 24, 717-730.e5	23.4	47
53	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. *Nature Communications*, **2018**, 9, 1928	17.4	46
52	A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge. *Cell Host and Microbe*, **2019**, 26, 336-346.e3	23.4	43

51	Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. *Cell Host and Microbe*, **2014**, 16, 412-8	23.4	41
50	Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients. *PLoS Pathogens*, **2015**, 11, e1004565	7.6	39
49	Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. *PLoS Pathogens*, **2016**, 12, e1005537	7.6	39
48	Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. *PLoS Pathogens*, **2017**, 13, e1006510	7.6	33
47	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. *Journal of Virology*, **2017**, 91,	6.6	30
46	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. *EBioMedicine*, **2016**, 14, 97-111	8.8	29
45	Wild bonobos host geographically restricted malaria parasites including a putative new Laverania species. *Nature Communications*, **2017**, 8, 1635	17.4	28
44	Multigenomic Delineation of Plasmodium Species of the Laverania Subgenus Infecting Wild-Living Chimpanzees and Gorillas. *Genome Biology and Evolution*, **2016**, 8, 1929-39	3.9	28
43	Contribution of proteasome-catalyzed peptide -splicing to viral targeting by CD8 T cells in HIV-1 infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 24748-24759	11.5	27
42	Pathogen-Associated Molecular Pattern Recognition of Hepatitis C Virus Transmitted/Founder Variants by RIG-I Is Dependent on U-Core Length. *Journal of Virology*, **2015**, 89, 11056-68	6.6	22
41	Fab-dimerized glycan-reactive antibodies are a structural category of natural antibodies. *Cell*, **2021**, 184, 2955-2972.e25	56.2	22
40	Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. *Science*, **2021**, 371,	33.3	22
39	Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes. *Virology*, **2015**, 475, 37-45	3.6	21
38	Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV Variants. *Viruses*, **2015**, 7, 5443-75	6.2	20
37	Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. *MBio*, **2015**, 6,	7.8	19
36	Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV Challenge. *Cell Reports*, **2020**, 31, 107624	10.6	19
35	SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques. *Journal of Virology*, **2020**, 94,	6.6	17
34	Derivation and Characterization of Pathogenic Transmitted/Founder Molecular Clones from Simian Immunodeficiency Virus SIVsmE660 and SIVmac251 following Mucosal Infection. *Journal of Virology* , **2016**, 90, 8435-53	6.6	16

33	Single-Genome Sequencing of Hepatitis C Virus in Donor-Recipient Pairs Distinguishes Modes and Models of Virus Transmission and Early Diversification. *Journal of Virology*, **2016**, 90, 152-66	6.6	16
32	Collapse of Cytolytic Potential in SIV-Specific CD8+ T Cells Following Acute SIV Infection in Rhesus Macaques. *PLoS Pathogens*, **2016**, 12, e1006135	7.6	15
31	Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. *PLoS Pathogens*, **2016**, 12, e1005879	7.6	14
30	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. *Science Translational Medicine*, **2021**, 13,	17.5	14
29	Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4. *MBio*, **2015**, 6, e02518	7.8	13
28	Superinfection and cure of infected cells as mechanisms for hepatitis C virus adaptation and persistence. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, E7139-E7148	11.5	13
27	Transmitted/founder hepatitis C viruses induce cell-type- and genotype-specific differences in innate signaling within the liver. *MBio*, **2015**, 6, e02510	7.8	13
26	Molecular characterization of a highly divergent HIV type 1 isolate obtained early in the AIDS epidemic from the Democratic Republic of Congo. *AIDS Research and Human Retroviruses*, **2001**, 17, 1217-22	1.6	13
25	Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology. *Journal of Virology*, **2019**, 93,	6.6	12
24	CD4 receptor diversity in chimpanzees protects against SIV infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 3229-3238	11.5	12
23	Low Multiplicity of HIV-1 Infection and No Vaccine Enhancement in VAX003 Injection Drug Users. *Open Forum Infectious Diseases*, **2014**, 1, ofu056	1	12
22	Simian-Human Immunodeficiency Virus SHIV.C.CH505 Persistence in ART-Suppressed Infant Macaques Is Characterized by Elevated SHIV RNA in the Gut and a High Abundance of Intact SHIV DNA in Naive CD4 T Cells. *Journal of Virology*, **2020**, 95,	6.6	11
21	Analytical Treatment Interruption after Short-Term Antiretroviral Therapy in a Postnatally Simian-Human Immunodeficiency Virus-Infected Infant Rhesus Macaque Model. *MBio*, **2019**, 10,	7.8	9
20	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. *PLoS Pathogens*, **2019**, 15, e1007632	7.6	9
19	The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection. *PLoS Pathogens*, **2021**, 17, e1009257	7.6	9
18	Simian-Human Immunodeficiency Virus SHIV.CH505-Infected Infant and Adult Rhesus Macaques Exhibit Similar Env-Specific Antibody Kinetics, despite Distinct T-Follicular Helper and Germinal Center B Cell Landscapes. *Journal of Virology*, **2019**, 93,	6.6	7
17	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure. *Journal of Virology*, **2021**,	6.6	7
16	Effective treatment of SIVcpz-induced immunodeficiency in a captive western chimpanzee. *Retrovirology*, **2017**, 14, 35	3.6	6

List of Publications

15	High multiplicity infection following transplantation of hepatitis C virus-positive organs. *Journal of Clinical Investigation*, **2019**, 129, 3134-3139	15.9	4
14	Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques		4
13	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.. *Cell Reports*, **2022**, 38, 110199	10.6	3
12	Molecular Identification of Transmitted/Founder Hepatitis C Viruses and Their Progeny by Single Genome Sequencing. *Methods in Molecular Biology*, **2019**, 1911, 139-155	1.4	3
11	Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primates. *PLoS Pathogens*, **2021**, 17, e1009736	7.6	3
10	Differential Outcomes following Optimization of Simian-Human Immunodeficiency Viruses from Clades AE, B, and C. *Journal of Virology*, **2020**, 94,	6.6	2
9	Estimating the Timing of Early Simian-Human Immunodeficiency Virus Infections: a Comparison between Poisson Fitter and BEAST. *MBio*, **2020**, 11,	7.8	2
8	Cryptic Multiple HIV-1 Infection Revealed by Early, Frequent, and Deep Sampling during Acute Infection. *AIDS Research and Human Retroviruses*, **2014**, 30, A58-A58	1.6	2
7	Simian Immunodeficiency Virus Infection in Free-Ranging Sooty Mangabeys (Cercocebus atys atys) from the Tai Forest, Co te dȘvoire: Implications for the Origin of Epidemic Human Immunodeficiency Virus Type 2. *Journal of Virology*, **2006**, 80, 4645-4645	6.6	2
6	Assessing routes of hepatitis C transmission in HIV-infected men who have sex with men using single genome sequencing. *PLoS ONE*, **2020**, 15, e0235237	3.7	2
5	Oral clade C SHIV challenge models to study pediatric HIV-1 infection by breastmilk transmission		1
4	CD4 receptor diversity represents an ancient protection mechanism against primate lentiviruses. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	1
3	New SHIVs and Improved Design Strategy for Modeling HIV-1 Transmission, Immunopathogenesis, Prevention and Cure		1
2	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. *Journal of Virology*, **2021**, 95, e0079621	6.6	1
1	Zoonotic origin of the human malaria parasite Plasmodium malariae from African apes.. *Nature Communications*, **2022**, 13, 1868	17.4	0